PT  - JOURNAL ARTICLE
AU  - Ariane Soldatos
AU  - Camilo Toro
AU  - Patrycja Hoffmann
AU  - Tina Romeo
AU  - Natalie Deuitch
AU  - Alessandra Brofferio
AU  - Ivona Aksentijevich
AU  - Daniel L. Kastner
AU  - Amanda K. Ombrello
TI  - TNF-Blockade for Primary Stroke Prevention in Adenosine Deaminase 2 Deficiency
AID  - 10.1212/NXI.0000000000200073
DP  - 2023 May 01
TA  - Neurology - Neuroimmunology Neuroinflammation
PG  - e200073
VI  - 10
IP  - 3
4099  - http://nn.neurology.org/content/10/3/e200073.short
4100  - http://nn.neurology.org/content/10/3/e200073.full
SO  - Neurol Neuroimmunol Neuroinflamm2023 May 01; 10
AB  - Objectives Adenosine deaminase 2 deficiency (DADA2) is a genetic, neurologic, and systemic vasculitis syndrome, which can lead to recurrent strokes, typically lacunar. In the cohort of now 60 patients followed up at the NIH Clinical Center (NIH CC), no patient has had a stroke since starting tumor necrosis factor (TNF) blockade. We present a family with multiple affected children to highlight the importance of TNF blockade not just as secondary stroke prevention but also as primary stroke prevention in genetically affected but clinically asymptomatic patients.Methods A proband with recurrent cryptogenic strokes was referred for evaluation at the NIH CC. The parents and 3 clinically asymptomatic siblings were also evaluated.Results The proband was diagnosed with DADA2 based on biochemical testing; her antiplatelet therapies were discontinued, and she was started on TNF blockade for secondary stroke prevention. Her 3 asymptomatic siblings were subsequently tested and 2 were found to be biochemically affected. One of them elected to start TNF blockade for primary stroke prevention and the other sibling declined this approach and experienced a stroke. A second genetic sequence variant was subsequently identified in the ADA2 gene.Discussion This family illustrates the importance of testing for DADA2 in young patients with cryptogenic stroke, given the hemorrhagic risks with antiplatelet drugs in these patients and effectiveness of TNF blockade as secondary stroke prevention. In addition, this family highlights the importance of screening all siblings of affected patients because they may be presymptomatic, and we advocate starting TNF blockade for primary stroke prevention in those who are found to be genetically or biochemically affected.